CMS finalized Transparency in Coverage updates as a researcher warns ghost rates and missing inpatient data limit payer price files.
News|Articles|May 13, 2026
5 Key Regulatory Shifts From Makary's Era at the FDA
Author(s)Pearl Steinzor
Fact checked by: Laura Joszt, MA
From rewriting drug approval standards to embedding AI in review workflows, former FDA commissioner Marty Makary, MD reshaped how evidence, speed, and access are balanced in US drug regulation.
Advertisement
Advertisement
The FDA has undergone a series of major policy shifts under Marty Makary, MD, MPH, who recently
Related to this article
A traditional Medicare out-of-pocket (OOP) cap could reduce beneficiaries’ costs but increase annual federal spending by $39 billion to $96 billion.
CMS is adding value-based care (VBC) risk faster than many providers can build the data and tech capacity they need to succeed.
Although PMOS Awareness Month has ended, the conversation continues, with experts saying closing diagnostic and care gaps requires ongoing efforts.
CMS finalized the mandatory GLOBE Model, tying Part B drug rebates to international prices in areas covering 25% of beneficiaries from Jan. 1, 2027.
FDA accepted United Therapeutics' sNDA for inhaled treprostinil in IPF. Here's what it could mean for patient access, coverage, and costs
Panelists ask whether cancer care will shift toward home-administered infusions as payers push for change. Other topics in this forward-looking session include new delivery tech and practice-led solutions.
Hepatitis reports after vaccination were more often serious in children, but the data lack dose counts and cannot show vaccine-specific risk.
Advertisement
Advertisement